| Pharmaceutical Information |
| Drug Name |
Istradefylline |
| Drug ID |
BADD_D02484 |
| Description |
Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy.[A184067] Unlike standard dopaminergic therapies for Parkinson's, Istradefylline targets adenosine A2A receptors in the basal ganglia.[A184067] This region of the brain is highly involved in motor control.[A184067]
Istradefylline is indicated as an adjunct treatment to [levodopa] and [carbidopa] for Parkinson's disease.[L8237]
This drug was first approved in Japan on 25 March 2013.[A184067] Istradefylline was granted FDA approval on 27 August 2019.[L8213] |
| Indications and Usage |
Not Available |
| Marketing Status |
Not Available |
| ATC Code |
N04CX01 |
| DrugBank ID |
DB11757
|
| KEGG ID |
D04641
|
| MeSH ID |
C111599
|
| PubChem ID |
5311037
|
| TTD Drug ID |
D0F4ZY
|
| NDC Product Code |
42747-604; 42747-602; 12079-2003 |
| Synonyms |
istradefylline | 8-(2-(3,4-dimethoxyphenyl)ethenyl)-1,3-diethyl-3,7-dihydro-7-methyl-1H-purine-2,6-dione | KW 6002 | KW-6002 |
|
| Chemical Information |
| Molecular Formula |
C20H24N4O4 |
| CAS Registry Number |
155270-99-8 |
| SMILES |
CCN1C2=C(C(=O)N(C1=O)CC)N(C(=N2)C=CC3=CC(=C(C=C3)OC)OC)C |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
